For many years scientists attempted to develop a topical formulation of dapsone that would be as effective against acne as oral dapsone, but without the hemolysis side effect. This was difficult to accomplish because dapsone is highly insoluble in aqueous solvents. In the early 2000s QLT USA developed Aczone, a 5% dapsone gel that was shown to be effective against acne without causing clinically significant declines in hemoglobin levels, even in subjects with G6PD deficiency. In February 2016, the FDA approved a 7.5% dapsone gel. This higher strength has the advantage of a once-daily application, versus twice-daily application of the 5% formulation. Other uses
Dapsone also find uses as a curing agent in the manufacture of paints, adhesives, composites, powder coats, printed circuit boards, and imine-based vitrimers. See also
Promin, a more-soluble derivative

References
External links
"Dapsone". Drug Information Portal. U.S. National Library of Medicine.
Borderline lepromatous leprosy is a skin condition with numerous, symmetrical skin lesions. : 346

See also
Leprosy
Cutaneous conditions

References


== External links ==